Topical Antiperspirant for Hand-Foot Syndrome

Topical Antiperspirant for Prevention of Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome) Associated With Capecitabine

The objectives of this study are to evaluate the effectiveness of an antiperspirant in preventing or attenuating the severity of palmer-plantar erythrodysesthesia associated with the Food and Drug Administration (FDA)-approved doses of capecitabine. The hypothesis is that cytotoxic compounds in sweat will be prevented from being deposited in the skin and causing chronic toxicity.

Inclusion Criteria:

• Has not previously received a regimen that includes 5-fluorouracil
• > 18 years old
• No known allergy or intolerance to Ban Unscented Roll-On Antiperspirant

Exclusion Criteria:

• < 18 years of age